Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "Serotonin receptor agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin (5-hydroxytryptamine; 5-HT), a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.
Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
The present invention is directed to novel compounds represented by structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.
Owner:BRISTOL MYERS SQUIBB CO
Compositions and methods for treating obesity and related disorders
InactiveUS20080255093A1Reduces unwanted side effectGood for weight lossBiocideNervous disorderSYMPATHOMIMETIC AGENTSSerotonin receptor agonist
The present invention is drawn to combinations of pharmaceutical agents having similar chemical and / or pharmacological properties, wherein the combinations maximize the therapeutic effect of the drug while minimizing their adverse effects. The methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) or bupropion in combination with an anti-epileptic agent (e.g., topiramate, zonisamide), CB1 antagonists (e.g., rimonabant), or a 5HT2C-selective serotonin receptor agonist, (e.g., lorcaserin) for the treatment of obesity and related conditions. The invention also features kits for use in the practice of these novel therapies.
Owner:VIVUS
Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).
Owner:BRISTOL MYERS SQUIBB CO
Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
The present application provides novel compounds according to Formula (I):including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).
Owner:BRISTOL MYERS SQUIBB CO
Processes for Preparing 3-Benzazepines
The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
Owner:ARENA PHARMA
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
Owner:BRISTOL MYERS SQUIBB CO
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
InactiveUS20080261922A1Preventing and ameliorating sleep-related breathing disorderBiocideNervous disorderNorepinephrine reuptake inhibitorPhosphate
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
The present invention provides processes and intermediates for the preparation of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and salts thereof which are useful as serotonin-2C (5-HT2C) receptor agonists for the treatment of, for example, obesity.
Owner:ARENA PHARMA
Method of stimulating the motility of the gastrointestinal system using ipamorelin
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
Owner:HELSINN THERAPEUTICS (U S) INC
Method of stimulating the motility of the gastrointestinal system using ipamorelin
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
Owner:HELSINN THERAPEUTICS (US) INC
Use of serotonin receptor agonists for treatment of movement disorders
InactiveUS20140243350A1Influences dopamine levelEffective influenceNervous disorderEster active ingredients5-HT1 receptorSerotonin receptor agonist
The present invention relates to the combined use of compounds which are activators of the KCNQ family potassium ion channels and compounds which are serotonin 5-HT1 receptor agonists. The combined use of KCNQ channel activators and 5-HT1 receptor agonists is useful in the treatment of for example movement disorders. The present invention further relates to pharmaceutical compositions, methods of treatments and kits of parts.
Owner:CONTERA PHARMA APS
Method of stimulating the motility of the gastrointestinal system using ipamorelin
InactiveUS20090143310A1Promote gastrointestinal motilityPeptide/protein ingredientsDigestive systemDiseaseOpioid antagonist
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
Owner:HELSINN THERAPEUTICS (US) INC
Combinations of serotonin receptor agonists for treatment of movement disorders
ActiveUS20130252965A1Effective treatmentEffective influenceOrganic active ingredientsNervous disorderSerotonin receptor agonistMedicine
The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
Owner:CONTERA PHARMA APS
Combinations of serotonin receptor agonists for treatment of movement disorders
InactiveUS20140221385A1Reduce AIMOrganic active ingredientsNervous disorderSerotonin receptor agonistPharmacology
The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
Owner:CONTERA PHARMA APS
Compositions and methods for treating ocular pathologies
PendingUS20200330405A1Reduce and ameliorate severityReduce and ameliorate and durationSenses disorderOintment deliverySerotoninSerotonin receptor agonist
This invention features compositions, methods, and kits for treating conditions associated with pathological ocular neovascularization, reducing scarring in the eye, treating dry eye, treating macular degeneration, and treating keratitis by administering a serotonin receptor agonist.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
Fixed Combination Dosage Forms for the Treatment of Migraine
InactiveUS20100016363A1Risk minimizationReduce morbidityBiocideNervous disorderRegimenSerotonin receptor agonist
Owner:APR APPLIED PHARMA RES
Acetylcholinesterase inhibitor compounds and 5ht4 serotonergic receptor agonists, with promnsia effect, methods for the preparation thereof and pharmaceutical compositions containing the same
Compounds are provided according to Formula (I)as well as their enantiomers and their racemics, their acid salts, their hydrates or their solvation products. Among a large number of possible meanings, X represents a halogen, Y an oxygen atom; all of the coefficients m, n, r and s have the value 1, R represents an ethyl and R′ a cycloalkyl. The invention also includes Methods of preparing the above compounds and the pharmaceutical compositions containing them also are provided.
Owner:UNIV CAEN
Combinations of serotonin receptor agonists for treatment of movement disorders
ActiveUS9186359B2Effective treatmentEffective influenceOrganic active ingredientsNervous disorderSerotonin receptor agonistTardive dyskinesia
The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
Owner:CONTERA PHARMA APS
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non-psychedelic / psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).
Owner:ARBORMENTIS LLC
Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Compositions and methods to reduce pathogenesis
InactiveUS20200078335A1Delay and inhibit neuronal reactivationPrevent viral reactivationSenses disorderPharmaceutical delivery mechanismSerotoninDisease
This invention is directed to compositions, methods and kits for ameliorating or reducing pathogenesis of a disease by administering to a subject a serotonin receptor agonist.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
A serotonin receptor agonist
ActiveCN106800550BStable in natureGood water solubilityOrganic active ingredientsSenses disorderSerotonin receptor agonistTryptamine Receptors
The invention provides a serotonin receptor agonist. Specifically, a tandospirone maleate compound is provided. The invention also provides the preparation method of the compound, as well as the pharmaceutical composition and application containing the compound. Tandospirone maleate provided by the present invention exists in the form of crystals, has stable properties, good water solubility, and significantly improved bioavailability, providing an effective solution for improving the safety and effectiveness of drugs; in addition , the preparation process of the compound of the present invention is simple, the yield is high, and it is suitable for industrial production.
Owner:SICHUAN CREDIT PHARMA +1
Phylloline derivatives and their pharmaceutical compositions and their application in pharmacy
ActiveCN106905300BOrganic active ingredientsNervous disorderSerotonin receptor agonistTryptamine Receptors
The invention belongs to the technical field of medicines, and in particular relates to anophylline derivatives (1-2), pharmaceutical compositions and preparation methods thereof, and such derivatives or pharmaceutical compositions as melatonin and 5-serotonin receptor agonists and its application in the preparation of antipsychotic drugs, especially in the preparation of drugs for treating or improving central nervous system diseases related to melatonin and 5-hydroxytryptamine receptors.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Method of stimulating the motility of the gastrointestinal system using ipamorelin
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
Owner:HELSINN HEALTHCARE SA
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non- psychedelic / psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).
Owner:ARBORMENTIS LLC
Compositions and methods for treating ocular pathologies
PendingCN110662549ASuppress diseaseInhibition formationSenses disorderPeptide/protein ingredientsSerotoninSerotonin receptor agonist
The invention features compositions, methods, and kits for treating conditions associated with pathological ocular neovascularization, reducing scarring in the eye, treating dry eye, treating maculardegeneration, and treating keratitis by administering a serotonin receptor agonist.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
Selective serotonin receptor inverse agonists as therapeutics for disease
Owner:ACADIA PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com